Plumas Q4 EPS $0.93 Up From $0.82 YoY

Plumas (NASDAQ:PLBC) reported quarterly earnings of $0.93 per share. This is a 13.41 percent increase over earnings of $0.82 per share from the same period last year.

byBill Haddad

January 19, 2022

1 minute read

Plumas (NASDAQ:PLBC) reported quarterly earnings of $0.93 per share. This is a 13.41 percent increase over earnings of $0.82 per share from the same period last year.

Air Canada Capacity Increased By 78% In Q2; Hopes On Lower Cash Burn, Ease On Travel Restrictions

By Akanksha

Today, 9:03 PM

Air Canada (OTC:ACDVF) reported second-quarter operating revenue growth of 59% year-over-year to C$837 million. Loss per share reduced to C$(3.31) compared…

ACDVF

Analysts Slash Latham Group’s Price Target, Still See Upside

By Akanksha

Today, 9:03 PM

Barclays analyst Matthew Bouley lowered Latham Group Inc’s (NASDAQ:SWIM) price target to $23 (implying an upside of 75%) from $37 and maintained an Overweight rating…

SWIM

Selecta Biosciences Announces Strategic Licensing Agreement With Takeda To Develop Next-Generation Gene Therapies For Patients With Lysosomal Storage Disorders

By Benzinga Newsdesk

Today, 9:03 PM

Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today

SELB

News

Enviva Responds To Short-Seller Report Late Wednesday. Claims The Report Contains Numerous Errors, Repeats Previous Unsupported Speculation And Gross Mischaracterizations, And Draws Specious, Misleading Conclusions

By Benzinga Newsdesk

Today, 9:03 PM

Enviva Inc. (NYSE:EVA) ("Enviva," "we," "us," the "Company," or "our"), the world's leading producer of sustainably sourced wood biomass, today issued the following

EVA

Plumas Q4 EPS $0.93 Up From $0.82 YoY

Related Posts

Air Canada Capacity Increased By 78% In Q2; Hopes On Lower Cash Burn, Ease On Travel Restrictions

Analysts Slash Latham Group’s Price Target, Still See Upside

Selecta Biosciences Announces Strategic Licensing Agreement With Takeda To Develop Next-Generation Gene Therapies For Patients With Lysosomal Storage Disorders

Enviva Responds To Short-Seller Report Late Wednesday. Claims The Report Contains Numerous Errors, Repeats Previous Unsupported Speculation And Gross Mischaracterizations, And Draws Specious, Misleading Conclusions